BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36305647)

  • 1. Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts.
    Wu WY; Haider Z; Feng X; Heath AK; Tjønneland A; Agudo A; Masala G; Robbins HA; Huerta JM; Guevara M; Schulze MB; Rodriguez-Barranco M; Vineis P; Tumino R; Kaaks R; Fortner RT; Sieri S; Panico S; Nøst TH; Sandanger TM; Braaten T; Johansson M; Melin B; Johansson M
    Int J Cancer; 2023 May; 152(9):2002-2010. PubMed ID: 36305647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.
    Feng X; Wu WY; Onwuka JU; Haider Z; Alcala K; Smith-Byrne K; Zahed H; Guida F; Wang R; Bassett JK; Stevens V; Wang Y; Weinstein S; Freedman ND; Chen C; Tinker L; Nøst TH; Koh WP; Muller D; Colorado-Yohar SM; Tumino R; Hung RJ; Amos CI; Lin X; Zhang X; Arslan AA; Sánchez MJ; Sørgjerd EP; Severi G; Hveem K; Brennan P; Langhammer A; Milne RL; Yuan JM; Melin B; Johansson M; Robbins HA; Johansson M
    J Natl Cancer Inst; 2023 Sep; 115(9):1050-1059. PubMed ID: 37260165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection in blood of autoantibodies to tumour antigens as a case-finding method in lung cancer using the EarlyCDT®-Lung Test (ECLS): study protocol for a randomized controlled trial.
    Sullivan FM; Farmer E; Mair FS; Treweek S; Kendrick D; Jackson C; Robertson C; Briggs A; McCowan C; Bedford L; Young B; Vedhara K; Gallant S; Littleford R; Robertson J; Sewell H; Dorward A; Sarvesvaran J; Schembri S
    BMC Cancer; 2017 Mar; 17(1):187. PubMed ID: 28284200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
    Borg M; Wen SWC; Nederby L; Hansen TF; Jakobsen A; Andersen RF; Weinreich UM; Hilberg O
    Lung Cancer; 2021 Aug; 158():85-90. PubMed ID: 34130044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Earlier diagnosis of lung cancer in a randomised trial of an autoantibody blood test followed by imaging.
    Sullivan FM; Mair FS; Anderson W; Armory P; Briggs A; Chew C; Dorward A; Haughney J; Hogarth F; Kendrick D; Littleford R; McConnachie A; McCowan C; McMeekin N; Patel M; Rauchhaus P; Ritchie L; Robertson C; Robertson J; Robles-Zurita J; Sarvesvaran J; Sewell H; Sproule M; Taylor T; Tello A; Treweek S; Vedhara K; Schembri S;
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32732334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of Lung Cancer Risk on the Basis of a Biomarker Panel of Circulating Proteins.
    ; Guida F; Sun N; Bantis LE; Muller DC; Li P; Taguchi A; Dhillon D; Kundnani DL; Patel NJ; Yan Q; Byrnes G; Moons KGM; Tjønneland A; Panico S; Agnoli C; Vineis P; Palli D; Bueno-de-Mesquita B; Peeters PH; Agudo A; Huerta JM; Dorronsoro M; Barranco MR; Ardanaz E; Travis RC; Byrne KS; Boeing H; Steffen A; Kaaks R; Hüsing A; Trichopoulou A; Lagiou P; La Vecchia C; Severi G; Boutron-Ruault MC; Sandanger TM; Weiderpass E; Nøst TH; Tsilidis K; Riboli E; Grankvist K; Johansson M; Goodman GE; Feng Z; Brennan P; Johansson M; Hanash SM
    JAMA Oncol; 2018 Oct; 4(10):e182078. PubMed ID: 30003238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
    Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Audit of the autoantibody test, EarlyCDT®-lung, in 1600 patients: an evaluation of its performance in routine clinical practice.
    Jett JR; Peek LJ; Fredericks L; Jewell W; Pingleton WW; Robertson JF
    Lung Cancer; 2014 Jan; 83(1):51-5. PubMed ID: 24268382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of a high throughput method of biomarker discovery to improvement of the EarlyCDT(®)-Lung Test.
    Macdonald IK; Murray A; Healey GF; Parsy-Kowalska CB; Allen J; McElveen J; Robertson C; Sewell HF; Chapman CJ; Robertson JF
    PLoS One; 2012; 7(12):e51002. PubMed ID: 23272083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum and blood based biomarkers for lung cancer screening: a systematic review.
    Chu GCW; Lazare K; Sullivan F
    BMC Cancer; 2018 Feb; 18(1):181. PubMed ID: 29439651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can autoantibody tests enhance lung cancer screening?-an evaluation of EarlyCDT
    González Maldonado S; Johnson T; Motsch E; Delorme S; Kaaks R
    Transl Lung Cancer Res; 2021 Jan; 10(1):233-242. PubMed ID: 33569307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium.
    Muller DC; Larose TL; Hodge A; Guida F; Langhammer A; Grankvist K; Meyer K; Cai Q; Arslan AA; Zeleniuch-Jacquotte A; Albanes D; Giles GG; Sesso HD; Lee IM; Gaziano JM; Yuan JM; Hoffman Bolton J; Buring JE; Visvanathan K; Le Marchand L; Purdue MP; Caporaso NE; Midttun Ø; Ueland PM; Prentice RL; Weinstein SJ; Stevens VL; Zheng W; Blot WJ; Shu XO; Zhang X; Xiang YB; Koh WP; Hveem K; Thomson CA; Pettinger M; Engström G; Brunnström H; Milne RL; Stampfer MJ; Han J; Johansson M; Brennan P; Severi G; Johansson M
    BMJ; 2019 Jan; 364():k4981. PubMed ID: 30606716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays.
    Chapman CJ; Healey GF; Murray A; Boyle P; Robertson C; Peek LJ; Allen J; Thorpe AJ; Hamilton-Fairley G; Parsy-Kowalska CB; MacDonald IK; Jewell W; Maddison P; Robertson JF
    Tumour Biol; 2012 Oct; 33(5):1319-26. PubMed ID: 22492236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective study of immune and inflammation markers and risk of lung cancer among female never smokers in Shanghai.
    Shiels MS; Shu XO; Chaturvedi AK; Gao YT; Xiang YB; Cai Q; Hu W; Shelton G; Ji BT; Pinto LA; Kemp TJ; Rothman N; Zheng W; Hildesheim A; Lan Q
    Carcinogenesis; 2017 Oct; 38(10):1004-1010. PubMed ID: 28981818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.
    Katki HA; Kovalchik SA; Petito LC; Cheung LC; Jacobs E; Jemal A; Berg CD; Chaturvedi AK
    Ann Intern Med; 2018 Jul; 169(1):10-19. PubMed ID: 29800127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer.
    Massion PP; Healey GF; Peek LJ; Fredericks L; Sewell HF; Murray A; Robertson JF
    J Thorac Oncol; 2017 Mar; 12(3):578-584. PubMed ID: 27615397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of motivation to quit in smokers screened for the early detection of lung cancer: a qualitative study.
    Young B; Vedhara K; Kendrick D; Littleford R; Robertson JFR; Sullivan FM; Schembri S; das Nair R;
    BMC Public Health; 2018 Nov; 18(1):1276. PubMed ID: 30453929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection of Lung Cancer [PanCan] study): a single-arm, prospective study.
    Tammemagi MC; Schmidt H; Martel S; McWilliams A; Goffin JR; Johnston MR; Nicholas G; Tremblay A; Bhatia R; Liu G; Soghrati K; Yasufuku K; Hwang DM; Laberge F; Gingras M; Pasian S; Couture C; Mayo JR; Nasute Fauerbach PV; Atkar-Khattra S; Peacock SJ; Cressman S; Ionescu D; English JC; Finley RJ; Yee J; Puksa S; Stewart L; Tsai S; Haider E; Boylan C; Cutz JC; Manos D; Xu Z; Goss GD; Seely JM; Amjadi K; Sekhon HS; Burrowes P; MacEachern P; Urbanski S; Sin DD; Tan WC; Leighl NB; Shepherd FA; Evans WK; Tsao MS; Lam S;
    Lancet Oncol; 2017 Nov; 18(11):1523-1531. PubMed ID: 29055736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein and risk of lung cancer.
    Chaturvedi AK; Caporaso NE; Katki HA; Wong HL; Chatterjee N; Pine SR; Chanock SJ; Goedert JJ; Engels EA
    J Clin Oncol; 2010 Jun; 28(16):2719-26. PubMed ID: 20421535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in oral microbiome is associated with future risk of lung cancer among never-smokers.
    Hosgood HD; Cai Q; Hua X; Long J; Shi J; Wan Y; Yang Y; Abnet C; Bassig BA; Hu W; Ji BT; Klugman M; Xiang Y; Gao YT; Wong JY; Zheng W; Rothman N; Shu XO; Lan Q
    Thorax; 2021 Mar; 76(3):256-263. PubMed ID: 33318237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.